Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2023-04-10 Capital/Financing Update
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
New Family 4 Patent to be Granted for RECCE Anti-Infectives 3 pages 273.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals Limited regarding the granting of a new patent family for their anti-infective products. It details the patent claims, the diseases targeted, and the company's intellectual property portfolio. There is no financial data, no mention of financial results, no regulatory certifications, or management changes. The content is focused on intellectual property and patent updates, which is typical for a capital/financing update or corporate announcement related to company assets. Given the nature of the announcement about patent grants and intellectual property, it fits best under Capital/Financing Update (CAP) as it relates to company assets and potential market exclusivity impacting valuation and financing. The document length is about 4950 characters, and it is a full announcement, not a brief note or a report publication announcement. Therefore, the classification is CAP with high confidence.
2023-04-10 English
Recce Receives Further A$973,144 R&D Advance 2 pages 224.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals Ltd dated 4 March 2023. It announces the receipt of a further A$973,144 advance payment related to the company's future Research and Development (R&D) tax incentive. The content focuses on a financing update regarding non-dilutive funds received from Radium Capital, which is a form of capital or financing activity. There are no financial statements, detailed financial results, or management discussion of financial performance. The document is relatively short (3240 characters) and is clearly an announcement of a financing event rather than a full report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-03 English
Corporate Presentation - WI Emergence 2023 25 pages 3.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation' and contains detailed information about the company's technology platform, pipeline, clinical milestones, board structure, and investment highlights. It includes forward-looking statements, disclaimers, and detailed scientific and clinical data. There is no indication that this is an official annual or interim financial report, audit report, or earnings release. The content is clearly designed to inform investors about the company's business, strategy, and market position. The length is substantial (15,000 characters), and the document is a presentation rather than a regulatory filing or announcement. Therefore, the document best fits the category of an Investor Presentation (IP).
2023-03-22 English
Appendix 4D and Interim Financial Report 23 pages 319.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2022' and contains detailed financial statements such as the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Directors' Report, Auditor's Independence Declaration, and notes to the financial statements. It covers a half-year period and includes substantive financial data and analysis. The presence of an auditor's review report further supports that this is a formal interim financial report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-02-26 English
Investor Presentation - Spark Plus Biotech Day 28 pages 4.0MB
Investor Presentation Classification · 100% confidence The document is an ASX announcement dated 24 February 2023, titled 'Spark Plus Biotech Day Investor Presentation'. It contains detailed presentation slides including company overview, pipeline, technology platform, and scientific data. The content is structured as a presentation aimed at investors, focusing on the company's strategy, product pipeline, and scientific research. There is no indication that this is a full financial report, audit, earnings release, or regulatory filing. The document is not a brief factsheet or a voting result announcement. It is clearly a detailed investor presentation as stated in the title and content. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) supports that it is a full presentation rather than a short announcement or notice.
2023-02-23 English
Recce Selects CMAX for Phase I/II UTI Clinical Trial 4 pages 396.7KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement detailing the selection of a clinical trial facility for a Phase I/II clinical trial of a pharmaceutical product. It discusses trial design, expected outcomes, and scientific background but does not contain financial data, regulatory certifications, or voting results. It is a corporate announcement about a clinical trial initiation rather than a financial report, regulatory filing, or management report. The content is focused on clinical trial progress and company development news, fitting best under a general regulatory announcement category rather than a specific financial or governance report.
2023-02-19 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.